The Faculty of Pharmacy of the University of Lisbon (FFUL) has shared new results within the Vax2Muc project, which aims to develop a mucosal vaccine against Helicobacter pylori and other gastrointestinal pathogens.
The study, presented by Tomás Concha Almeida, PhD student at FFUL, focused on the production of chitosan nanoparticles, which, due to their positive charge, can deliver vaccines to the gastrointestinal mucosa. Using a Design of Experiments approach, researchers identified the optimal conditions to consistently produce high-quality nanoparticles.
These findings mark an important step towards the development of a vaccine able to withstand the stomach’s harsh environment and trigger local immunity.
The Vax2Muc project brings together a multidisciplinary and international team, with Portugal represented by researchers António Almeida (Principal Investigator and Researcher) and Lídia Maria Diogo Gonçalves (Researcher) from the iMed.Ulisboa research group Advanced Technologies for Drug Delivery.
